Britain’s most promising businesses are being held back by surging employment costs and persistent difficulties attracting skilled workers, new research has found. A survey of 423 leaders of high-growth companies by Enterprise
Lupin Pharmaceuticals, the U.S. unit of India-based Lupin Limited, has issued a voluntary recall of more than 2.5 million bottles of prescription eye drops following the discovery of an undisclosed contaminant. The
More
A bipartisan bill that recently passed the U.S. House of Representatives could fundamentally alter how private-sector employers negotiate first contracts with newly unionised workforces. The Faster Labor Contracts Act would impose mandatory
More
Brandon Etheridge, the former general counsel for the Baltimore Ravens, has joined a major Biglaw firm to help build and lead its growing sports law practice. Etheridge brings substantial insider knowledge to
More
Building a meaningful second income no longer requires a winning performance at Wimbledon or a City bonus cheque. The FTSE 100 has delivered an average annualised total return of around 6.9% since
More
The U.S. Food and Drug Administration has issued a proposed rule that would create a streamlined registration pathway for distributed drug manufacturing establishments operating under a hub-and-spoke model. Under the current regulatory
More
Nevada’s Supreme Court has overturned a key piece of caselaw governing how contingency fee attorneys’ fees are awarded following successful offers of judgment. The ruling, handed down in Clark v. Marin on
More
Legal professionals face mounting pressure to adopt artificial intelligence tools, with negligence claims now a potential consequence of failing to do so in practice. The question of whether a lawyer can be
More
Global equity markets came under pressure as rising geopolitical tensions involving Iran rattled investor sentiment across major US indices on Wednesday. The S&P 500 and Nasdaq Composite both recorded losses as traders
More
Investors searching for income are increasingly turning to FTSE 250 stocks as Cash ISA rates continue to disappoint savers across the United Kingdom. One particular FTSE 250 stock has drawn attention for
More
Hengrui Pharma and Elevar Therapeutics have received a third complete response letter from the FDA for their camrelizumab and rivoceranib combination therapy. The rejection marks more than two years of regulatory setbacks
More